NeurologyLive® Friday 5 — July 22, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Treating Familial ALS at the Source: The Introduction of Gene Therapies

As scientific researchers continue to uncover new genetic links to amyotrophic lateral sclerosis, the rise of gene therapies to treat the neuromuscular disease will remain a development to watch in the coming years.

2: The Need for More Time in Movement Disorder Care: Temitope Lawal, MD

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about the need for clinicians to have more time with patients in clinical practice, particularly with those with chronic diseases.

3: NeuroVoices: Lindsey Lee Lair, MD, on the Phase 3 RESILIENT Trial of Taldefgropeb Alfa in SMA

The vice president of clinical development at Biohaven provided insight on a new phase 3 study assessing a muscle-targeted agent as an adjunct therapy to currently approved spinal muscular atrophy medications.

4: Tackling the Global Issue of Ancestral Disparities in Alzheimer Disease: Margaret Pericak-Vance, PhD

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared toward understanding the genetic differences of underrepresented groups.

5: The Treatment of Status Migrainosus in Emergency Care Settings: Matthew Robbins, MD

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the state of treatment for status migrainosus and whether or not the new migraine medications can help improve care.

—————————————————